Skip to search formSkip to main contentSkip to account menu

MPT0E028

Known as: HDAC Inhibitor MPT0E028, MPT 0E028, MPT-0E028 
An orally bioavailable N-hydroxyacrylamide-derived inhibitor of both human pan-histone deacetylase (HDAC) enzymes and the serine/threonine protein… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Correction: Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo
In the original version of this article (1), the authors provided incorrect files for Figs. 1E, 4, 5B, and 6E. In Fig. 1E… 
2014
2014
Synergistic Interaction between the HDAC Inhibitor, MPT0E028, and Sorafenib in Liver Cancer Cells In Vitro and In Vivo
Purpose: To investigate the antitumor activities of a histone deacetylase (HDAC) inhibitor, MPT0E028, plus sorafenib in liver… 
2014
2014
Cancer Therapy : Preclinical Synergistic Interaction between the HDAC Inhibitor , MPT 0 E 028 , and Sorafenib in Liver Cancer Cells In Vitro and In Vivo
Purpose: To investigate the antitumor activities of a histone deacetylase (HDAC) inhibitor, MPT0E028, plus sorafenib in liver… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)